Previous 10 | Next 10 |
2024-01-17 07:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-09 11:40:35 ET More on Madrigal, Viking, etc. Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap Madrigal Pharmaceuticals: Preparing For Resmetirom's Commerci...
2024-01-09 09:45:02 ET Wells Fargo analyst issues BUY recommendation for BPMC on January 9, 2024 10:00AM ET. The previous analyst recommendation was Buy. BPMC was trading at $83.615 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire -- AYVAKIT ® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. la...
2024-01-04 16:28:54 ET Summary Today, we take a look at Blueprint Medicines Corporation, whose shares have nearly doubled in the past two months due to strong sales of its precision medicine Ayvakit. Ayvakit's label expansion into indolent systemic mastocytosis suggests blockbuste...
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-22 12:00:02 ET Raymond James analyst issues STRONG BUY recommendation for BPMC on December 22, 2023 12:00PM ET. The previous analyst recommendation was Strong Buy. BPMC was trading at $88.13 at issue of the analyst recommendation. The overall analyst consensus : ...
2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland , Chief Executive Officer, will pres...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...